New phase 3 data support the FDA approval of lumateperone, showing early efficacy and favorable tolerability as an adjunctive treatment for MDD.
Suresh Durgam, MD
Advertisement
Suresh Durgam, MD: chief medical officer of Intra-Cellular Therapies
Articles by Suresh Durgam, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
First Half 2026 Recap: Dermatology
2
From Red-Cheeked Baby to Bulbous Nose: Rosacea, Start to Finish
3
Guideline-Directed Care Improves Limb Outcomes in Peripheral Artery Disease
4
Navigating a New Era of PH Management as an APP, With Susanne McDevitt, DNP
5